Table 3.
Multivariable regression analysis assessing factors associated with antibody levels (AU/mL Log).
| Variable | β (SE) | %95 CI | P |
|---|---|---|---|
| Sex (female vs male) | −0.046 (0.137) | −0.315–0.223 | .737 |
| Age | −0.004(0.007) | −0.018–0.009 | .501 |
| Vaccine type | |||
| 2 Dose Inactivated Vaccine+1 Dose mRNA BNT162b2 Vaccine | reference | ||
| 3 Dose Inactivated Vaccine | −0.671 (0.133) | −0.933 – −0.409 | <0.001 |
| TBVS | 0.000 (0.001) | −0.002–0.002 | .761 |
| EDSS | −0.031(0.043) | −0.115–0.053 | .472 |
| Disease duration | −0.019 (0.010) | −0.038–0.000 | .044 |
| MS course (Relapsing vs progressive) | −0.223 (0.212) | −0.640–0.195 | .295 |
| DMT | <0.001 | ||
| Mean difference | |||
| No treatment | Reference | ||
| Glatiramer acetate | −0.379 (0.347) | −1.496–0.739 | >0.99 |
| Interferons | −0.694 (0.352) | −1.829–0.440 | >0.99 |
| Teriflunomide | −0.743 (0.379) | −1.966–0.481 | >0.99 |
| Dimethyl fumarate | −0.413 (0.397) | −1.694–0.869 | >0.99 |
| Fingolimod | 0.957 (0.328) | −0.102–2.016 | 0.138 |
| Cladribine | −0.588 (0.493) | −2.179–1.003 | >0.99 |
| Natalizumab | −0.441 (0.354) | −1.583–0.701 | >0.99 |
| Ocrelizumab | 1.957 (0.327) | 0.901–3.013 | <0.001 |